Inovio Pharmaceuticals’ (NASDAQ:INO) Buy Rating Reaffirmed at Aegis
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)‘s stock had its “buy” rating reissued by stock analysts at Aegis in a note issued to investors on Tuesday. They presently have a $14.00 price objective on the biopharmaceutical company’s stock. Aegis’ target price suggests a potential upside of 80.18% from the stock’s current price.
A number of other research analysts also recently weighed in on INO. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, June 3rd. Piper Jaffray Companies raised Inovio Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $14.00 price target on the stock in a research note on Thursday, June 8th. Jefferies Group LLC reaffirmed a “neutral” rating and set a $38.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. BNP Paribas reaffirmed a “neutral” rating and set a $39.00 price objective on shares of Inovio Pharmaceuticals in a research note on Monday, May 1st. Finally, Zacks Investment Research raised Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective on the stock in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. Inovio Pharmaceuticals has an average rating of “Buy” and a consensus target price of $19.90.
Inovio Pharmaceuticals (NASDAQ INO) traded up 1.03% during mid-day trading on Tuesday, hitting $7.85. The stock had a trading volume of 394,312 shares. The stock has a 50 day moving average of $7.75 and a 200-day moving average of $6.89. The firm’s market cap is $585.82 million. Inovio Pharmaceuticals has a 1-year low of $5.83 and a 1-year high of $11.00.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.31). The firm had revenue of $10.40 million for the quarter, compared to analyst estimates of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The business’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period last year, the company earned ($0.11) EPS. Analysts predict that Inovio Pharmaceuticals will post ($1.10) EPS for the current fiscal year.
In related news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $8.00, for a total transaction of $64,000.00. Following the completion of the transaction, the director now owns 740,956 shares in the company, valued at $5,927,648. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 10.60% of the company’s stock.
A number of large investors have recently modified their holdings of the company. Private Capital Advisors Inc. bought a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at about $274,000. Credit Suisse AG increased its stake in shares of Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 69,068 shares during the period. Metropolitan Life Insurance Co. NY increased its stake in shares of Inovio Pharmaceuticals by 8.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock valued at $341,000 after buying an additional 4,020 shares during the period. Bank of America Corp DE increased its stake in shares of Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after buying an additional 3,605 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Inovio Pharmaceuticals by 5.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 305,844 shares of the biopharmaceutical company’s stock valued at $2,025,000 after buying an additional 16,845 shares during the period. Hedge funds and other institutional investors own 27.74% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.